Navigation Links
Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
Date:10/20/2009

by the administration of tamoxifen in estrogen dependent breast cancer cells. Moreover, this study shows that tamoxifen inhibits the recruitment of important coregulatory proteins to the receptor, which demonstrates that the effect observed is directly due to the interaction of tamoxifen with ERb.

"It is critical to develop new strategies to prevent and treat breast cancer. The knowledge we obtained from the positive clinical effects of tamoxifen combined with recent discoveries of the different roles played by the two estrogen receptors is critical for the future generation of therapies for this important indication," said Dr. Isaac Cohen, Chairman and CEO of Bionovo, Inc. "Bionovo has been developing methods to discover more selective drugs for breast cancer treatment and prevention and, to date, has identified numerous ERb-selective drugs. Dr. Leitman's study provides the biological rationale for advancing ERb drugs for the treatment of breast cancer, which we feel will be important, novel therapies for this indication."

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward-Looking Statements

This release contains c
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
2. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
3. Bionovo Announces First Quarter 2009 Highlights and Financial Results
4. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
5. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
6. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
7. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
8. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
9. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
10. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
11. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... TechniScan, Inc. (OTC Bulletin ... device company engaged in the development and commercialization ... today that Joe Pepper, PhD, has been appointed ... Board Chairman Ken Hungerford commented, "Joe has extensive ... including GE OEC Medical and U-Systems, both of ...
(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... Phase I clinical trial of its lead compound ... in the study. GLYX-13, a glycine site ... NMDA receptor, is initially being developed as a ...
(Date:12/16/2009)... PALO ALTO, Calif., Dec. 16 The ... Intradigm Corporation are delighted to announce the merger ... in the field of RNAi (RNA interference). ... will have multiple RNAi discovery, development and delivery ... and a broad portfolio of intellectual property. ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6Ortho Clinical Diagnostics Receives FDA Approval for First Anti HIV 1+2 Test for Use on Random Access Integrated Laboratory Testing System 5472 1Ortho Clinical Diagnostics Receives FDA Approval for First Anti HIV 1+2 Test for Use on Random Access Integrated Laboratory Testing System 5472 2Ortho Clinical Diagnostics Receives FDA Approval for First Anti HIV 1+2 Test for Use on Random Access Integrated Laboratory Testing System 5472 3Ortho Clinical Diagnostics Receives FDA Approval for First Anti HIV 1+2 Test for Use on Random Access Integrated Laboratory Testing System 5472 4Experts summarize state of the science in autism disorders 59459 1Experts summarize state of the science in autism disorders 59459 2Miriam Hospital researcher receives more than 2412 million to study weight control 10359 1Miriam Hospital researcher receives more than 2412 million to study weight control 10359 2Miriam Hospital researcher receives more than 2412 million to study weight control 10359 3
... Plan for Biomarker Study -, MONTVALE, N.J., ... ) today announced that it plans to,conduct a ... nicotinic alpha-7,partial agonist, on two biomarkers of schizophrenia, ... schizophrenia. The biomarker study,and additional formulation and manufacturing ...
... Detecting the ... Mosquito-Borne Infectious Disease, CYPRESS, Calif., Feb. 15 Focus ... DGX ),today announced the first laboratory developed test in ... molecular polymerase chain reaction (PCR) test will enable physicians,in the ...
Other Medicine Technology:Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 2Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 3Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia 4Focus Diagnostics Launches Laboratory Test for Chikungunya Virus 2Focus Diagnostics Launches Laboratory Test for Chikungunya Virus 3Focus Diagnostics Launches Laboratory Test for Chikungunya Virus 4
(Date:12/16/2009)... and MassBio promote Massachusetts companies through annual marketing campaign ... ... 2009 -- BioSpace unveiled the 2010 Genetown™ Hotbed Campaign ... , , , ,Genetown is sponsored by MassBio ... device industries. The campaign places each entity’s brand on an ...
(Date:12/16/2009)... children are uninsured, government report finds , , WEDNESDAY, Dec. ... of this year, 45.4 million Americans of all ages ... no health insurance, according to new National Health Interview ... (19.4 percent) people of all ages had been uninsured ... the interview, and 31.9 million (10.6 percent) had been ...
(Date:12/16/2009)... 16 Shoppers like knowing if their ... Argentina. But grocers have found it burdensome to ... laws requiring them to provide the information at ... easyCOOLnow.com for easily making grocery and ... provisions that require retailers of unprocessed fruits, vegetables ...
(Date:12/16/2009)... Medical travel facilitator Companion Global Healthcare ... Rico into its network of international hospitals that ... those at mainland U.S. facilities. ,, The announcement ... assistance and preferred pricing for its individual clients ... either HIMA San Pablo Bayamon or HIMA San ...
(Date:12/16/2009)... New research published online, December 10, 2009 ... molecules present in pistachios, have anti-inflammatory properties. ... an inflammatory marker known as "Ifit-2" (INF-induced ... a complex biological response to harmful stimuli, ... underlies functional changes associated with many chronic ...
Breaking Medicine News(10 mins):Health News:Thriving Bioscience Region Leaves Its Mark 2Health News:Over 45 Million Americans Now Lack Health Insurance 2Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3
... has adopted a positive opinion recommending the granting of ... Vaccines and Diagnostics unit. ,Focetria is ... of influenza during an officially declared pandemic situation, once ... the second mock-up pandemic influenza vaccine to receive a ...
... extremely optimistic about the recent changes introduced at hospitals with ... waiting time for patients. , ,As part of the ... in the emergency rooms in hospitals. A "bed site manager" ... to manage beds for patients who need to be shifted ...
... should be given a higher priority and more funding, ... people in Southeast Asia suffer from tropical diseases such ... emerging as another important problem in the region. ... have considerable economic impact on populations that are already ...
... and improve movement in a mouse model of spinal muscular ... the NIH’s National// Institute of Neurological Disorders and Stroke (NINDS), ... treating human SMA. ,"This study shows that treatment ... Kenneth H. Fischbeck, M.D., of the NINDS, who helped lead ...
... of Patricia Rooper, who died following a 'delayed reaction' to ... has revealed that radiation had caused her death last year ... diagnosed with cancer of the left breast in 1971 when ... to intensive radiotherapy at Hammersmith hospital in London. There she ...
... Although the government has approved meat and milk from cloned ... Dallas// said Thursday that its customers and consumers don't want ... O'Lakes and Horizon Organic, among dozens of other brands. ... interested in buying dairy products that contain milk from cloned ...
Other Medicine News:Health News:WHO Urges Higher Priority for Neglected Diseases 2Health News:Treatment Extends Survival in Mouse Model of Spinal Muscular Atrophy 2Health News:Treatment Extends Survival in Mouse Model of Spinal Muscular Atrophy 3Health News:‘Delayed Reaction’ to Radiation Therapy Takes the Life of a Woman After 30 Yea 2Health News:Milk from Cloned Cows is Not Welcome at the Nation's Biggest Milk Company 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: